Literature DB >> 28676945

Verification of the tumor volume delineation method using a fixed threshold of peak standardized uptake value.

Kazuya Koyama1,2, Takuya Mitsumoto3, Takahiro Shiraishi3, Keisuke Tsuda4, Atsushi Nishiyama1, Kazumasa Inoue2, Kyosan Yoshikawa3, Kazuo Hatano3, Kazuo Kubota5, Masahiro Fukushi6.   

Abstract

We aimed to determine the difference in tumor volume associated with the reconstruction model in positron-emission tomography (PET). To reduce the influence of the reconstruction model, we suggested a method to measure the tumor volume using the relative threshold method with a fixed threshold based on peak standardized uptake value (SUVpeak). The efficacy of our method was verified using 18F-2-fluoro-2-deoxy-D-glucose PET/computed tomography images of 20 patients with lung cancer. The tumor volume was determined using the relative threshold method with a fixed threshold based on the SUVpeak. The PET data were reconstructed using the ordered-subset expectation maximization (OSEM) model, the OSEM + time-of-flight (TOF) model, and the OSEM + TOF + point-spread function (PSF) model. The volume differences associated with the reconstruction algorithm (%VD) were compared. For comparison, the tumor volume was measured using the relative threshold method based on the maximum SUV (SUVmax). For the OSEM and TOF models, the mean %VD values were -0.06 ± 8.07 and -2.04 ± 4.23% for the fixed 40% threshold according to the SUVmax and the SUVpeak, respectively. The effect of our method in this case seemed to be minor. For the OSEM and PSF models, the mean %VD values were -20.41 ± 14.47 and -13.87 ± 6.59% for the fixed 40% threshold according to the SUVmax and SUVpeak, respectively. Our new method enabled the measurement of tumor volume with a fixed threshold and reduced the influence of the changes in tumor volume associated with the reconstruction model.

Entities:  

Keywords:  Positron-emission tomography; Reconstruction; Threshold; Tumor volume

Mesh:

Substances:

Year:  2017        PMID: 28676945     DOI: 10.1007/s12194-017-0405-6

Source DB:  PubMed          Journal:  Radiol Phys Technol        ISSN: 1865-0333


  26 in total

1.  Segmentation of PET volumes by iterative image thresholding.

Authors:  Walter Jentzen; Lutz Freudenberg; Ernst G Eising; Melanie Heinze; Wolfgang Brandau; Andreas Bockisch
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 2.  Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis.

Authors:  Kyoungjune Pak; Gi Jeong Cheon; Hyun-Yeol Nam; Seong-Jang Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  J Nucl Med       Date:  2014-04-21       Impact factor: 10.057

3.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.

Authors:  Ursula Nestle; Stephanie Kremp; Andrea Schaefer-Schuler; Christiane Sebastian-Welsch; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch
Journal:  J Nucl Med       Date:  2005-08       Impact factor: 10.057

4.  Impact of the definition of peak standardized uptake value on quantification of treatment response.

Authors:  Matt Vanderhoek; Scott B Perlman; Robert Jeraj
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

5.  Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.

Authors:  Ernesto Brianzoni; Gloria Rossi; Sergio Ancidei; Alfonso Berbellini; Francesca Capoccetti; Carla Cidda; Paola D'Avenia; Sara Fattori; Gian Carlo Montini; Gianluca Valentini; Alfredo Proietti; Carlo Algranati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

6.  Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.

Authors:  Mathieu Hatt; Catherine Cheze-le Rest; Angela van Baardwijk; Philippe Lambin; Olivier Pradier; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-10-11       Impact factor: 10.057

7.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

8.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?

Authors:  Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

9.  Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma.

Authors:  Ronan Abgral; Nathalie Keromnes; Philippe Robin; Pierre-Yves Le Roux; David Bourhis; Xavier Palard; Jean Rousset; Gérald Valette; Rémi Marianowski; Pierre-Yves Salaün
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

10.  Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET.

Authors:  Go Akamatsu; Katsuhiko Mitsumoto; Takafumi Taniguchi; Yuji Tsutsui; Shingo Baba; Masayuki Sasaki
Journal:  Eur J Radiol       Date:  2013-10-06       Impact factor: 3.528

View more
  1 in total

1.  Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.

Authors:  Sebastian Meißner; Jan-Carlo Janssen; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Frank Hofheinz; Marcus R Makowski
Journal:  EJNMMI Res       Date:  2017-10-23       Impact factor: 3.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.